Live feed07:00:00·1577dPRReleasevia QuantisnowObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated PainByQuantisnow·Wall Street's wire, on your screen.OBSV· ObsEva SAHealth Care
